Mechanism of action & use of daratumumab in multiple myeloma

Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, gives an overview of the mechanism of action of daratumumab in multiple myeloma, commenting on its use in the frontline and relapsed/refractory (R/R) settings in transplant-eligible and transplant-ineligible patients. This interview took place at the 38th World Congress of the International Society of Hematology (ISH) 2022.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.